Parker Highlander’s biotechnology practice group focuses on end-to-end patent prosecution and portfolio development relating to the entire breadth of biotechnology, including molecular biology, next-generation sequencing, personalized medicine, diagnostics, stem cell biology, immunotherapeutics, and biologics. Important practice considerations include proactive approaches to addressing subject matter eligibility concerns in light of the recent Mayo and Myriad Supreme Court decisions. Our group builds on a broad and diverse skill set, which includes advanced academic degrees and research experience in the fields of molecular biology, neuroscience, virology, immunology, and drug development.